ReviewJournal of stroke2022
Therapeutic Trends of Cerebrovascular Disease during the COVID-19 Pandemic and Future Perspectives.
Review in Journal of stroke, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04934020 (Global Impact of the COVID 19 Pandemic on Stroke Care), which is not on this map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Global Impact of the COVID 19 Pandemic on Stroke Care: 1-year Follow-up Study
Who cites it
9 citing papers in PubMed, 21 citations in OpenAlex.
- The stroke meta-metric, Defect-Free Care, was maintained year-over-year within the Florida stroke registry during the COVID-19 pandemic.Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association · 2025Article
- Review
- Article
- Recent Updates on COVID-19 Associated Strokes.Neuroscience insights · 2024Review
- Cerebrovascular Disease in COVID-19.Viruses · 2023Review
- Global Impact of the COVID-19 Pandemic on Stroke Volumes and Cerebrovascular Events: A 1-Year Follow-up.Neurology · 2023Observational
- Outcome Prediction in Cerebral Venous Thrombosis: The IN-REvASC Score.Journal of stroke · 2022Article
- Global Impact of the COVID-19 Pandemic on Cerebral Venous Thrombosis and Mortality.Journal of stroke · 2022Article
- The Impact of COVID-19 Pandemic on Ischemic Stroke Patients in a Comprehensive Hospital.Risk management and healthcare policy · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
As of May 2022, there have been more than 400 million cases (including re-infections) of the systemic acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), and nearly 5 million deaths worldwide. Not only has the coronavirus disease 2019 (COVID-19) pandemic been responsible for diagnosis and treatment delays of a wide variety of conditions, and overwhelmed the allocation of healthcare resources, it has impacted the epidemiology and management of cerebrovascular disease. In this narrative review, we summarize the changing paradigms and latest data regarding the complex relationship between COVID-19 and cerebrovascular disease. Paradoxically, although SARS-CoV-2 has been associated with many thrombotic complications-including ischemic stroke-there have been global declines in ischemic stroke and other cerebrovascular diseases. These epidemiologic shifts may be attributed to patient avoidance of healthcare institutions due to fear of contracting the novel human coronavirus, and also related to declines in other transmissible infectious illnesses which may trigger ischemic stroke. Despite the association between SARS-CoV-2 and thrombotic events, there are inconsistent data regarding targeted antithrombotics to prevent venous and arterial events. In addition, we provide recommendations for the conduct of stroke research and clinical trial planning during the ongoing COVID-19 pandemic, and for future healthcare crises.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.